ARTV Stock Analysis: Buy, Sell, or Hold?
ARTV - Artiva Biotherapeutics, Inc. Common Stock
$11.52
0.59 (5.40%)
â˛
5d:
-1.87%
30d:
+14.86%
90d:
+46.38%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ARTV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ARTV is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ARTV is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ARTV is currently trading at $11.52, which is considered slightly high relative to its 30-day fair value range of $10.11 to $11.58.
Technical Outlook: Technically, ARTV is in a uptrend. Immediate support is located at $10.49, while resistance sits at $12.27. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: ARTV scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (91th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $35.80 (+210.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ARTV is in a uptrend. Immediate support is located at $10.49, while resistance sits at $12.27. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: ARTV scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (91th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $35.80 (+210.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$10.11 -
$11.58
Company Quality Score
47/100
(HOLD)
Options IV Signal
91th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
37.5%
All Signals
- BEARISH: Options expensive (IV 91th percentile)
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 210.8% below Wall St target ($35.80)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.11 -
$11.58
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$3.52
(30.6%)
Support & Resistance Levels
Support Level
$10.49
Resistance Level
$12.27
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.42
Wall Street Target
$35.80
(+210.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 25, 2026 4:27 AM ET
Data refreshes hourly during market hours. Next update: 5:27 AM
Data refreshes hourly during market hours. Next update: 5:27 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARTV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 39 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 40 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 62 BUY |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 48 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
BUY
20 analysts |
$34 | 47 HOLD |
